Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 1, 2006, Pages 59-65

  Meyerhardt, Jeffrey A ^a   Heseltine, Denise ^a   Ogino, Shuji ^a   Clark, Jeffrey W ^b   Enzinger, Peter C ^a   Ryan, David P ^b   Earle, Craig C ^a   Zhu, Andrew X ^b   Fuchs, Charles S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

5 fluorouracil; Erlotinib; Gefitinib; Irinotecan; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MEDICAL RECORD; METASTASIS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33745911892     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.022     Document Type: Article

References (32)

1. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20:1S-13S.
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799.
3. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
4. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
5. Hemming AW, Davis NL, Kluftinger A, et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51:147-152.
6. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-6565.
7. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-187.
8. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). N Engl J Med 2004; 351:337-345.
10. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
11. Dorligschaw O, Kegel T, Jordan K, et al. ZD 1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22:372 (Abstract #1494).
12. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
13. Hightower M, Klem J, Lee D. Epidermal growth factor receptor in not correlated with prognosis in patients with metastatic colorectal cancer treated with erlotinib (OSI-774, Tarceva). Clin Colorectal Cancer 2003; 3:10-11.
14. Rothenberg ML, Lafleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005; 23:9265-9274.
15. Hanauske A-R, Diaz-Rubio E, Cassidy J, et al. Erlotinib HCL in combination with FOLFOX4 in patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:197 (Abstract #789).
16. Meyerhardt JA, Zhu A, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2004; 23:265 (Abstract #3580).
17. Kuo T, Cho CD, Halsey J, et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:5613-5619.
18. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003; 21:2237-2246.
19. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
21. Lilenbaum R, Bonomi P, Ansari R, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results. J Clin Oncol 2005; 23(16 suppl):629s (Abstract #7036).
22. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3510).
23. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005; 11:6650-6656.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
25. Minna JD, Peyton MJ, Gazdar AF. Gefitinib versus cetuximab in lung cancer: round one. J Natl Cancer Inst 2005; 97:1168-1169.
26. Blanke CD. Gefitinib in colorectal cancer: if wishes were horses. J Clin Oncol 2005; 23:5446-5449.
27. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445-2459.
28. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97:1185-1194.
29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
30. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
31. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351:2883.
32. Tuma RS. New studies look beyond EGFR mutations for clues to sensitivity to erlotinib. J Natl Cancer Inst 2005; 97:1028-1029.